In a significant policy shift, the United States Food and Drug Administration's (FDA) has suggested revisions to the labelling of menopausal hormone treatments (MHT), generally known as hormone replacement therapy (HRT). The move intends to provide women and clinicians with better, more balanced information about the advantages and hazards of these medicines, which are routinely used to treat hot flashes, nocturnal sweats, and vaginal discomfort associated with menopause. 

A thorough examination of scientific data, including long-term findings from the Women's Health Initiative (WHI) research, led to the FDA's decision. These studies, which started in the 1990s, previously showed that using a combination of oestrogen and progestin could raise the chances of breast cancer and heart problems, while oestrogen alone was linked to a higher risk of stroke and dementia in older women. As a result, in 2003, the agency required prominent box warnings on all hormone products, emphasising the importance of using the lowest feasible dose for the shortest term. 

However, new research suggests that such concerns may not apply equally to younger menopausal women—typically aged 45–55— who start hormone therapy soon after menopause. The original WHI research concentrated mostly on women in their sixties and seventies, a demographic already predisposed to age-related illnesses. The FDA now understands that this mismatch may have resulted in unwarranted fear and underuse of MHT among women who would benefit the most. 

According to US Census data, around 41 million women aged 45 to 64 have menopausal symptoms, yet only about two million receive hormone therapy prescriptions. Many people refuse therapy because of anxieties based on previous warnings, although symptoms including hot flashes, night sweats, and vaginal dryness can have a negative impact on quality of life. 

After engaging with an expert panel in July 2025 and examining public feedback, the FDA is now looking to remove many obsolete warning statements from MHT labels. The FDA suggests removing references to cardiovascular disease, breast cancer, and likely dementia from the boxed warnings and updating the text to better reflect current research. Systemic oestrogen-only products will continue to have endometrial cancer warning labels. 

According to health experts, the modifications may enable patients and clinicians to engage in more nuanced discussions. By clarifying which hazards apply to which age groups, the FDA seeks to restore trust in a medicine that, when used correctly, can greatly improve women's well-being throughout menopause.